ArticleAmerican heart journal plus : cardiology research and practice2026
Real-world impact of coronary artery calcium scoring on primary prevention management in a community cardiology practice.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objective: To evaluate the impact of coronary artery calcium (CAC) scoring on lipid-lowering therapy intensification, aspirin initiation, and downstream cardiac testing in primary prevention patients in a community cardiology setting. Design: Retrospective observational study. Setting: Single community cardiology practice. Participants: Four hundred consecutive patients undergoing CAC scoring in 2022. Interventions: CAC scoring used for risk stratification and clinical decision-making. Main outcome measures: Changes in lipid-lowering therapy, aspirin initiation, and downstream cardiac testing across CAC categories (0, 1-99, 100-399, ≥400); risk reclassification using Pooled Cohort Equations (PCE) and Multi-Ethnic Study of Atherosclerosis (MESA) risk scores. Results: Among 400 patients (mean age 60.2 ± 10.6 years; 46.5% male), 30% had CAC = 0, 37% CAC 1-99, 18% CAC 100-399, and 16% CAC ≥400. Lipid therapy modification increased across categories (7.7%, 33.3%, 69.0%, 81.7%; Conclusions: CAC burden was independently associated with graded intensification of lipid-lowering therapy, aspirin initiation, and downstream testing after multivariable adjustment, extending prior descriptive literature with persistent, quantified associations in real-world community practice. Improvement in clinical outcomes cannot be assessed from this retrospective, six-month implementation study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.